PBFT-02 is under clinical development by Passage Bio and currently in Phase II for Frontotemporal Dementia (FTD). According to GlobalData, Phase II drugs for Frontotemporal Dementia (FTD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PBFT-02 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PBFT-02 overview
PBFT-02 is under development for the treatment of rare monogenic central nervous system disorder including adult neurodegenerative diseases FTD-C9orf72, frontotemporal dementia, Alzheimer's disease and amyotrophic lateral sclerosis. It comprises of an adeno-associated virus vector 1 (AAV1) capsid to deliver functional GRN gene encoding progranulin (PGRN). It is administered by intra-cisterna magna injection.
Passage Bio overview
Passage Bio is a genetic medicines company that develops therapies for the treatment of monogenic central nervous system disorders. The company’s pipeline products include PBGM01 injection to treat GM1 gangliosidosis, PBFT02 targets frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease; and PBAL05 for the treatment of neurodegenerative disease. Passage Bio works in collaboration with the University of Pennsylvania and its gene therapy program (GTP) for preclinical works. Its manufacturing and global clinical distribution center is located at Hopewell, New Jersey. Passage Bio is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of PBFT-02’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
